DexCom, Inc. (NASDAQ:DXCM) Given Average Recommendation of “Buy” by Analysts

Shares of DexCom, Inc. (NASDAQ:DXCM) have been given an average rating of “Buy” by the seventeen analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $454.94.

DXCM has been the topic of several recent research reports. UBS Group upgraded shares of DexCom from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $410.00 to $445.00 in a research report on Wednesday, January 6th. Piper Sandler raised their price target on shares of DexCom from $465.00 to $500.00 and gave the stock an “overweight” rating in a report on Friday, January 29th. Canaccord Genuity lifted their price objective on shares of DexCom from $445.00 to $455.00 and gave the company a “buy” rating in a research note on Friday. TheStreet lowered shares of DexCom from a “b-” rating to a “c” rating in a research note on Thursday, April 29th. Finally, Raymond James lifted their price objective on shares of DexCom from $449.00 to $466.00 and gave the company an “outperform” rating in a research note on Friday.

In related news, CFO Quentin S. Blackford sold 6,509 shares of the business’s stock in a transaction dated Wednesday, March 10th. The stock was sold at an average price of $362.22, for a total value of $2,357,689.98. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Nicholas Augustinos sold 1,875 shares of the business’s stock in a transaction dated Tuesday, February 16th. The shares were sold at an average price of $412.03, for a total value of $772,556.25. Following the completion of the sale, the director now owns 806 shares in the company, valued at $332,096.18. The disclosure for this sale can be found here. Insiders sold a total of 34,192 shares of company stock worth $12,681,786 over the last three months. 0.69% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in the stock. Cowen AND Company LLC bought a new stake in DexCom in the 1st quarter valued at about $1,283,000. Envestnet Asset Management Inc. increased its position in shares of DexCom by 31.9% during the first quarter. Envestnet Asset Management Inc. now owns 122,474 shares of the medical device company’s stock valued at $44,016,000 after buying an additional 29,615 shares during the period. Oak Ridge Investments LLC increased its position in shares of DexCom by 973.4% during the first quarter. Oak Ridge Investments LLC now owns 29,938 shares of the medical device company’s stock valued at $10,759,000 after buying an additional 27,149 shares during the period. GVO Asset Management Ltd bought a new stake in shares of DexCom during the first quarter valued at about $48,000. Finally, Alamar Capital Management LLC increased its position in shares of DexCom by 11.9% during the first quarter. Alamar Capital Management LLC now owns 7,523 shares of the medical device company’s stock valued at $2,704,000 after buying an additional 798 shares during the period. Institutional investors and hedge funds own 94.06% of the company’s stock.

NASDAQ:DXCM traded down $9.15 during mid-day trading on Thursday, hitting $371.42. 42,337 shares of the company’s stock were exchanged, compared to its average volume of 830,056. The company has a 50 day simple moving average of $377.84 and a 200-day simple moving average of $368.81. The company has a current ratio of 6.39, a quick ratio of 6.00 and a debt-to-equity ratio of 1.10. DexCom has a fifty-two week low of $305.63 and a fifty-two week high of $456.23. The firm has a market capitalization of $35.92 billion, a P/E ratio of 151.60, a PEG ratio of 6.15 and a beta of 0.86.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 29th. The medical device company reported $0.33 EPS for the quarter, topping the consensus estimate of $0.31 by $0.02. DexCom had a net margin of 12.69% and a return on equity of 27.29%. As a group, analysts expect that DexCom will post 3.07 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system.

Featured Story: Hedge Funds – How They Work For Investors

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.